

ASX ANNOUNCEMENT (ASX: RSH)

23rd February 2023

**RESPIRI USA MEDICAL ADVISORY BOARD ESTABLISHED TO SUPPORT PRODUCT & CLINICAL DEVELOPMENT AND FURTHER HELP ADVANCE wheezo® REMOTE PATIENT MONITORING AS PART OF STANDARD OF CARE**

**Highlights:**

- Respi USA Medical Advisory Board (MAB) established with leading US-based Respiratory Key Opinion Leaders.
- MAB to provide strategic guidance on wheezo® Respiratory Remote Patient Monitoring, Clinical Research & Development and New Product Development.

Respi Limited (ASX:RSH; OTCQB:RSHUF) (“Respi” or the “Company”), an eHealth SaaS Company supporting respiratory health management, is pleased to announce that it has formed a Medical Advisory Board (MAB) with leading US Key Opinion Leaders (KOL) who will help forge the Company’s respiratory clinical and product development strategies and guidance on further advancing wheezo® Remote Patient Monitoring (RPM) program as part of standard patient respiratory care.

The MAB will be key in supporting the Respi’s expansion in the US by enhancing wheezo® RPM healthcare utility, investigate clinical applications for the new product pipeline and provide strategic counsel and recommendations for the company’s US-centric plans including the introduction of key institutions.

The founding MAB members comprise a wealth of experience and knowledge and a diverse skill set spanning clinical pulmonology, scientific & clinical expertise and commercial medical device development and commercialisation.

**William S. Krinsky, FCCP, DAABIP** will serve as the MAB’s first Chair and is a highly respected expert in interventional pulmonology and in the use of electromagnetic navigation bronchoscopy for the diagnosis and treatment of lung disease. He has developed innovative techniques to treat diseases of the chest, and he travels nationally and internationally to teach these techniques. He also is medical director of clinical research at Pulmonary and Critical Care Associates of Baltimore. Dr. Krinsky specializes in robotic surgery and innovative treatments for lung cancer.

Over the course of his career, Dr Krinsky has been lead investigator for several national clinical trials. He has received several awards for his work, including recognition by the New England Respiratory Research Competition and Awards Program for Excellence in Research in Respiratory Medicine. He is board certified in internal medicine, pulmonary disease, and critical care medicine, and he has specialty certification in interventional pulmonology. Dr. Krinsky is a fellow of the American College of Chest Physicians and is an active member of several professional societies, including the American College of Chest Physicians, the Society of Critical Care Medicine, and the American Thoracic Society. During his career, he has been invited to speak at more than 50 congresses, events and other medical forums. In addition to his work in the United States, Dr. Krinsky has travelled to teach navigational bronchoscopy to physicians in China.

The newly appointed Medical Advisory Board members are:

**Professor Gerard J. Criner, MD, FACP, FACC**P Chair and Professor, Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University. Dr. Gerard Criner received his medical degree from Temple University School of Medicine his clinical specialties include advanced lung diseases, airway disorders, COPD, interstitial lung disease, lung volume reduction, and lung transplantation. In 2015 he became the founding chair of the Department of Thoracic Medicine and Surgery. Dr. Criner has extensive experience in conducting, designing, and leading multicentre trials for the past 25 years. He has been involved in multiple NIH steering committees, ad hoc technical panels, and work groups over the past 20 years. He has also developed several multicentred trials with industry that includes the use of lung coils (PneumRX), tissue glue (AERIS) and endobronchial valves to reduce hyperinflation in

emphysema (LIBERATE, Pulmonx). Dr. Criner has been recognized as part of the Best Doctors in America®, Pulmonary Medicine; Critical Care Medicine in 2015-2016, 2017-2018, 2019-2020.

Professor Criner also has a very strong interest in respiratory remote patient monitoring, developing a patient self-reported, clinically validated RPM program which has been successfully implemented at Temple University Hospital involving more than 3,000 patients. The possible inclusion of wheezo® into this program to input objective real time patient data from the real world into the clinical algorithm is an area of further investigation.

Temple Health, a large and prestigious healthcare institution, comprises 979 licensed hospital beds and provides services for 34,000 hospital admissions, 165,000 emergency room visits and more than 340,000 outpatient visits per year.

**Ass. Professor Stephen Selinger, MD**, is a graduate of the Johns Hopkins University School of Medicine. He is an assistant professor at Georgetown University Medical Center, as well as a clinical instructor at Johns Hopkins University. Dr. Selinger is the Chief Medical Officer for Luminis Health Anne Arundel Medical Center. Dr. Selinger serves as the physician executive for Luminis Health Anne Arundel Medical Center, Luminis Health J. Kent McNew Family Medical Center, and Luminis Health Pathways. Established in 1902 and located in Annapolis, Maryland, Luminis employees >6,500 staff, has 3 hospitals with 611 licensed beds and over 80 care sites accommodating in excess of 156,000 emergency visits per annum and almost 36,000 inpatient admissions, generating USD\$1.1BN pa in operating revenue.

Prior to joining LHAAMC, Dr. Selinger served as the Chairman of the Department of Medicine, Director of the Critical Care and Medical Service Line, and Chairman of the Department of Medicine. At LHAAMC, he plays a critical role in medical staff governance, quality, safety, education, leader development, physician engagement, financial performance, and medical director partnerships.

Dr Selinger also share very strong interest and experience in developing respiratory RPM programs and has implemented such a program in an aged care facility within the Luminis group.

**Dr. Jonathan Hovda, M.D., M.B.A** graduated from Medical School at the University of Minnesota, where he simultaneously also received a Master of Business Administration degree from the Carlson School of Management. He completed his residency in Internal Medicine at Abbott North-western Hospital in Minneapolis and fellowships in Pulmonary/Critical Care Medicine and Interventional Pulmonology at Wake Forest University in Winston-Salem, NC. He brings with him a perspective founded on a unique blend of clinical, medical and business backgrounds.

Dr. Hovda has special interests in lung cancer and advanced bronchoscopy, including robotic bronchoscopy and endobronchial ultrasound. He is board-certified in Internal Medicine, Pulmonary Disease and Critical Care Medicine. He practices both inpatient and outpatient Pulmonary Medicine, and sees patients at our Fridley, Edina, Minneapolis and Plymouth offices.

Mr Marjan Mikel, MD and CEO Respiro stated: "We are delighted to welcome such a high calibre team of experts that add another level of sophistication to our strategy as we continue to execute our US plans. I am looking forward to working with them and learning much from them."

- ENDS -

For further information, investors and media please contact:

**Mr Marjan Mikel**  
CEO & Managing Director  
Respiro Limited  
P: +61 408 462 873  
E: [marjan@respiro.co](mailto:marjan@respiro.co)

**Mr Nicholas Smedley**  
Executive Chairman  
Respiro Limited  
P: +61 447 074 160  
E: [nicholas@respiro.co](mailto:nicholas@respiro.co)

*This ASX announcement has been authorised for release by the Board of Directors of Respi Limited.*

## **About Respi Limited**

Respi is an e-Health SaaS company supporting respiratory health management. Its world-first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. wheezo®, Respi's innovative technology, comprises an eHealth app combined with a simple, easy to use, handheld device. wheezo® is the first smart device to help improve asthma management by monitoring wheeze and documenting symptoms, signs, triggers, weather conditions and medication use. The asthma management platform also facilitates the sharing of data with caregivers, physicians and other health care professionals.

Respi's mission is to help improve quality of life for hundreds of millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. Respi Limited's operations are based in Melbourne, Australia.

For additional information about Respi and its products, please visit [www.respi.co](http://www.respi.co)

## **About wheezo®**

Developed in Australia, with the support of respiratory specialists and other healthcare professionals, the innovative wheezo® device analyses breath sounds for wheeze, and the eHealth App assists patients with managing their asthma by tracking symptoms, triggers, medication use and geo-specific weather conditions. The platform has been designed to extend asthma management beyond the clinic and make it easy to share information with doctors and make appropriate adjustments to asthma action plans. Better active management may lead to better outcomes and improved quality of life for the asthma patient.

For further information about wheezo®, follow the online link <https://wheezo.com>

wheezo® is a registered trademark of Respi Limited.

## **Forward Looking Statements**

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on Respi current expectations, estimates and projections about the industry in which Respi operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Respi, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Respi cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Respi only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Respi will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.